Spain · Delayed Price · Currency is EUR Inozyme Pharma Statistics
Total Valuation
BME:XUSIO has a market cap or net worth of EUR 889.22 million. The enterprise value is 1.62 billion.
| Market Cap | 889.22M |
| Enterprise Value | 1.62B |
Important Dates
The last earnings date was Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 702.73M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 584.75M |
Valuation Ratios
The trailing PE ratio is 15.13 and the forward PE ratio is 9.42.
| PE Ratio | 15.13 |
| Forward PE | 9.42 |
| PS Ratio | 0.21 |
| PB Ratio | 0.21 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 6.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.66, with an EV/FCF ratio of -94.39.
| EV / Earnings | 27.50 |
| EV / Sales | 0.38 |
| EV / EBITDA | 4.66 |
| EV / EBIT | 10.18 |
| EV / FCF | -94.39 |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.31.
| Current Ratio | 4.16 |
| Quick Ratio | 2.46 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 4.46 |
| Debt / FCF | -77.30 |
| Interest Coverage | 0.96 |
Financial Efficiency
Return on equity (ROE) is 1.99% and return on invested capital (ROIC) is 1.27%.
| Return on Equity (ROE) | 1.99% |
| Return on Assets (ROA) | 1.10% |
| Return on Invested Capital (ROIC) | 1.27% |
| Return on Capital Employed (ROCE) | 1.94% |
| Revenue Per Employee | 317,664 |
| Profits Per Employee | 4,461 |
| Employee Count | 13,175 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 3.44 |
Taxes
In the past 12 months, BME:XUSIO has paid 24.61 million in taxes.
| Income Tax | 24.61M |
| Effective Tax Rate | 22.84% |
Stock Price Statistics
The stock price has decreased by -20.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -20.62% |
| 50-Day Moving Average | 0.71 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 76.17 |
| Average Volume (20 Days) | 6,568 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BME:XUSIO had revenue of EUR 4.19 billion and earned 58.78 million in profits. Earnings per share was 0.05.
| Revenue | 4.19B |
| Gross Profit | 343.73M |
| Operating Income | 110.33M |
| Pretax Income | 107.76M |
| Net Income | 58.78M |
| EBITDA | 290.60M |
| EBIT | 110.33M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 1.05 billion in cash and 1.32 billion in debt, giving a net cash position of -269.89 million.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 1.32B |
| Net Cash | -269.89M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.24B |
| Book Value Per Share | 3.08 |
| Working Capital | 2.14B |
Cash Flow
In the last 12 months, operating cash flow was 128.74 million and capital expenditures -145.87 million, giving a free cash flow of -17.12 million.
| Operating Cash Flow | 128.74M |
| Capital Expenditures | -145.87M |
| Free Cash Flow | -17.12M |
| FCF Per Share | n/a |
Margins
Gross margin is 8.21%, with operating and profit margins of 2.64% and 1.40%.
| Gross Margin | 8.21% |
| Operating Margin | 2.64% |
| Pretax Margin | 2.57% |
| Profit Margin | 1.40% |
| EBITDA Margin | 6.94% |
| EBIT Margin | 2.64% |
| FCF Margin | n/a |
Dividends & Yields
BME:XUSIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 12.71% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 6.61% |
| FCF Yield | -1.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 28, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Sep 28, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
BME:XUSIO has an Altman Z-Score of 1.82 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 7 |